Research funding
Our research is primarily funded by...
- German Research Foundation (DFG) | www.dfg.de
- German Cancer Aid (DKH) | www.krebshilfe.de
- Wilhelm Sander Foundation | www.wilhelm-sander-stiftung.de
- Bavarian Research Foundation (BFS) | www.forschungsstiftung.de
Some examples of third-party funding:
Research scholarship
June 2023
Dr. Christina Bruss has successfully received a research grant as part of the "Breast Cancer" funding program offered by Gilead Sciences GmbH. Title of the funded project:
"Immune checkpoint profiling of T lymphocytes – multiple checkpoints and their potential relevance in immunotherapy in breast cancer"
Funded project continuation
Jan 2023
The Wilhelm Sander Foundation is funding a project continuation (applicant: Prof. Dr. Gero Brockhoff, co-applicant: Prof. Dr. Anja K. Wege) with a new focus:
"Verification of the HER4 receptor as a predictive biomarker for the treatment of estrogen receptor-positive breast cancer with tamoxifen and abemaciclib - preclinical in vitro and in vivo studies."
(Duration 1 year: 06/2023 - 06/2024)
Third-party funding
Jan 2021
Prof. Dr. Gero Brockhoff, together with Prof. Dr. Anja K. Wege (co-applicant), is applying for third-party funding for the following project from the Wilhelm Sander Foundation:
"Endocrine therapy with tamoxifen dependent on HER4 receptor expression - preclinical treatment studies in vitro and in vivo."
(Duration 2 years: 06/2021 - 06/2023)
Extensive project funding
2019 - 2023
Prof. Dr. Gero Brockhoff and Prof. Dr. Anja K. Wege have secured extensive project funding from the DFG (total funding > €0.5 million).
"Assessment of the impact of low dose solid tumor irradiation on tumor growth, metastases, immune cell activation, and subsequent immunotherapy in a humanized tumor mouse model"
Consortium project "Translational Oncology"
2015 - 2018
Brockhoff & Wege: A research project within a consortium was funded by the German Cancer Aid:
"Evaluation of geno- and phenotypic alterations in Luminal B breast cancer using Humanized Tumor mice (HTM)"
Consortium project:
"Evaluation of new Diagnostic and Therapeutic strategies In high risk luminal Breast cancer (TransLUMINAL-B).(Fördersumme ges.: 2 Mio €)
Cooperation funding from the BFS
2013 - 2016
Brockhoff & Wege: The Bavarian Research Foundation (BFS) funded a joint project with MABDiscovery GmbH (now IcanoMAB GmbH) and Agrobiogen GmbH: "Generation and characterization of innovative, monoclonal anti-ErbB receptor antibodies (anti-ErbB mAbs) with increased therapeutic potential for antigen-specific tumor cell treatments/therapies."
(Project volume: ~1.2 million €, group funding volume 0.58 million €)